Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 79

1.

Markedly Increased High-Mobility Group Box 1 Protein in a Patient with Small-for-Size Syndrome.

Craig DG, Lee P, Pryde EA, Hidalgo E, Hayes PC, Wigmore SJ, Forbes SJ, Simpson KJ.

Case Rep Transplant. 2014;2014:272498. doi: 10.1155/2014/272498. Epub 2014 Jan 29.

PMID:
24600525
[PubMed]
Free PMC Article
2.

Clinical chorioamnionitis is characterized by changes in the expression of the alarmin HMGB1 and one of its receptors, sRAGE.

Romero R, Chaiworapongsa T, Savasan ZA, Hussein Y, Dong Z, Kusanovic JP, Kim CJ, Hassan SS.

J Matern Fetal Neonatal Med. 2012 Jun;25(6):558-67. doi: 10.3109/14767058.2011.599083.

PMID:
22578261
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Increased levels of soluble receptor for advanced glycation end products (sRAGE) and high mobility group box 1 (HMGB1) are associated with death in patients with acute respiratory distress syndrome.

Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Maeda S, Yamagishi S.

Clin Biochem. 2011 Jun;44(8-9):601-4. doi: 10.1016/j.clinbiochem.2010.12.014. Epub 2011 Jan 3.

PMID:
21211520
[PubMed - indexed for MEDLINE]
4.

Plasma concentrations of high-mobility group box protein 1, soluble receptor for advanced glycation end-products and circulating DNA in patients with acute pancreatitis.

Kocsis AK, Szabolcs A, Hofner P, Takács T, Farkas G, Boda K, Mándi Y.

Pancreatology. 2009;9(4):383-91. doi: 10.1159/000181172. Epub 2009 May 19.

PMID:
19451748
[PubMed - indexed for MEDLINE]
5.

High levels of circulating HMGB1 as a biomarker of acute liver failure in patients with viral hepatitis E.

Majumdar M, Ratho R, Chawla Y, Singh MP.

Liver Int. 2013 Oct;33(9):1341-8. doi: 10.1111/liv.12197. Epub 2013 May 19.

PMID:
23682703
[PubMed - indexed for MEDLINE]
6.

Dietary advanced glycation end-products, its pulmonary receptor, and high mobility group box 1 in aspiration lung injury.

Smit PJ, Guo WA, Davidson BA, Mullan BA, Helinski JD, Knight PR 3rd.

J Surg Res. 2014 Sep;191(1):214-23. doi: 10.1016/j.jss.2014.04.001. Epub 2014 Apr 8.

PMID:
24814199
[PubMed - in process]
7.

Circulating levels of a soluble form of receptor for advanced glycation end products and high-mobility group box chromosomal protein 1 in patients with acute pancreatitis.

Lindström O, Tukiainen E, Kylänpää L, Mentula P, Rouhiainen A, Puolakkainen P, Rauvala H, Repo H.

Pancreas. 2009 Nov;38(8):e215-20. doi: 10.1097/MPA.0b013e3181bb59a7.

PMID:
19786934
[PubMed - indexed for MEDLINE]
8.

Elevation of high-mobility group box 1 after clinical autologous islet transplantation and its inverse correlation with outcomes.

Itoh T, Iwahashi S, Kanak MA, Shimoda M, Takita M, Chujo D, Tamura Y, Rahman AM, Chung WY, Onaca N, Coates PT, Dennison AR, Naziruddin B, Levy MF, Matsumoto S.

Cell Transplant. 2014 Feb;23(2):153-65. doi: 10.3727/096368912X658980. Epub 2012 Dec 4.

PMID:
23211332
[PubMed - in process]
Free PMC Article
9.

The plasma level of soluble receptor for advanced glycation end products is decreased in patients with systemic lupus erythematosus.

Ma CY, Ma JL, Jiao YL, Li JF, Wang LC, Yang QR, You L, Cui B, Chen ZJ, Zhao YR.

Scand J Immunol. 2012 Jun;75(6):614-22. doi: 10.1111/j.1365-3083.2012.02691.x.

PMID:
22324318
[PubMed - indexed for MEDLINE]
10.

Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients.

Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Ueda Y, Suzuki T, Yamada S, Takeuchi M, Fukami K, Ueda S, Adachi H, Matsui T, Okuda S, Yamagishi S.

Metabolism. 2009 Nov;58(11):1624-8. doi: 10.1016/j.metabol.2009.05.018. Epub 2009 Jul 15.

PMID:
19604520
[PubMed - indexed for MEDLINE]
11.

Impact of serum high mobility group box 1 and soluble receptor for advanced glycation end-products on subclinical atherosclerosis in patients with granulomatosis with polyangiitis.

Souza AW, de Leeuw K, van Timmeren MM, Limburg PC, Stegeman CA, Bijl M, Westra J, Kallenberg CG.

PLoS One. 2014 Apr 28;9(4):e96067. doi: 10.1371/journal.pone.0096067. eCollection 2014.

PMID:
24776932
[PubMed - in process]
Free PMC Article
12.

Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control.

Pullerits R, Bokarewa M, Dahlberg L, Tarkowski A.

Arthritis Res Ther. 2005;7(4):R817-24. Epub 2005 Apr 25.

PMID:
15987483
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Suppression of high-mobility group box-1 and receptor for advanced glycation end-product axis by polymyxin B-immobilized fiber hemoperfusion in septic shock patients.

Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Maeda S, Yamagishi S.

J Crit Care. 2011 Dec;26(6):546-9. doi: 10.1016/j.jcrc.2010.11.010. Epub 2011 Jan 26.

PMID:
21273029
[PubMed - indexed for MEDLINE]
14.

The receptor for advanced glycation endproducts and its ligands in patients with myasthenia gravis.

Moser B, Bekos C, Zimprich F, Nickl S, Klepetko W, Ankersmit J.

Biochem Biophys Res Commun. 2012 Mar 30;420(1):96-101. doi: 10.1016/j.bbrc.2012.02.121. Epub 2012 Mar 3.

PMID:
22405771
[PubMed - indexed for MEDLINE]
15.

Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients.

Yan XX, Lu L, Peng WH, Wang LJ, Zhang Q, Zhang RY, Chen QJ, Shen WF.

Atherosclerosis. 2009 Aug;205(2):544-8. doi: 10.1016/j.atherosclerosis.2008.12.016. Epub 2008 Dec 14.

PMID:
19150066
[PubMed - indexed for MEDLINE]
16.
17.

Circulating levels of advanced glycation end products (AGE) and interleukin-6 (IL-6) are independent determinants of serum asymmetric dimethylarginine (ADMA) levels in patients with septic shock.

Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Suzuki T, Ueda Y, Yamada S, Shoji H, Takeuchi M, Ueda S, Matsui T, Adachi H, Okuda S, Yamagishi S.

Pharmacol Res. 2009 Dec;60(6):515-8. doi: 10.1016/j.phrs.2009.05.002. Epub 2009 May 18.

PMID:
19450686
[PubMed - indexed for MEDLINE]
18.

High mobility group box 1 promotes small intestinal damage induced by nonsteroidal anti-inflammatory drugs through Toll-like receptor 4.

Nadatani Y, Watanabe T, Tanigawa T, Machida H, Okazaki H, Yamagami H, Watanabe K, Tominaga K, Fujiwara Y, Arakawa T.

Am J Pathol. 2012 Jul;181(1):98-110. doi: 10.1016/j.ajpath.2012.03.039. Epub 2012 May 22.

PMID:
22634181
[PubMed - indexed for MEDLINE]
Free Article
19.

Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis.

Kim JK, Park S, Lee MJ, Song YR, Han SH, Kim SG, Kang SW, Choi KH, Kim HJ, Yoo TH.

Atherosclerosis. 2012 Jan;220(1):208-14. doi: 10.1016/j.atherosclerosis.2011.07.115. Epub 2011 Aug 5.

PMID:
21906738
[PubMed - indexed for MEDLINE]
20.

Soluble receptor for advanced glycation end products (sRAGE) and endogenous secretory RAGE (esRAGE) in amniotic fluid: modulation by infection and inflammation.

Romero R, Espinoza J, Hassan S, Gotsch F, Kusanovic JP, Avila C, Erez O, Edwin S, Schmidt AM.

J Perinat Med. 2008;36(5):388-98. doi: 10.1515/JPM.2008.076.

PMID:
18593373
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk